Skip To Main Content
EpiSwitch CiRT on Muck Rack

EpiSwitch CiRT

As seen in: FE Investegate
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to EpiSwitch CiRT’s profile

Articles by EpiSwitch CiRT

Business update for PSE and CiRT tests

|
By Oxford Biodynamics Plc, Jon Burrows, EpiSwitch CiRT
| FE Investegate Verified
We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms. I Agree Wednesday 05 April, 2023 Oxford BioDynamics Business update for PSE and CiRT tests RNS Number : 3939V Oxford BioDynamics PLC 05 April 2023 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Open in Who Shared View Duplicates (315) Issue with article?

Business update for PSE and CiRT tests

|
By EpiSwitch CiRT
| sharesmagazine.co.uk
Oxford BioDynamics Plc Business update - plan to launch Prostate Screening EpiSwitch® test by end of 2023; sales progress for flagship EpiSwitch® CiRT · Acceleration of final development and launch of PSE clinical test in both UK and US, for availability in Q4 2023 · Flagship EpiSwitch CiRT (Checkpoint inhibitor Response Test) continuing to gain traction in the US, posting record orders in November and December 2022, and January and March 2023 · Leased US lab space for own CLIA-certified LDT...
Open in Who Shared View Duplicates (2) Issue with article?
Show More